Structure of the catalytic domain of human polo-like kinase 1

Biochemistry

Volumn 46, Issue 20, 2007, Pages 5960-5971

  Kothe, Michael ^a   Kohls, Darcy ^a   Low, Simon ^a   Coli, Rocco ^a   Cheng, Alan C ^a   Jacques, Suzanne L ^a   Johnson, Theresa L ^a   Lewis, Cristina ^a,b   Loh, Christine ^a   Nonomiya, Jim ^a,b   Sheils, Alissa L ^a   Verdries, Kimberly A ^a   Wynn, Thomas A ^a   Kuhn, Cyrille ^a   Ding, Yuan Hua ^a  

^a PFIZER INC   (United States)

^b GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICANCER AGENTS; CELL-CYCLE PROGRESSION; CYSTEINE; PHENYLALANINE;

CRYSTAL STRUCTURE; DRUG DELIVERY; MUTAGENS; NUCLEOTIDES; ONCOLOGY;

ENZYME INHIBITION;

ADENINE; ADENOSINE TRIPHOSPHATE DERIVATIVE; ADENYLYLIMIDODIPHOSPHATE; CYSTEINE; LEUCINE; MUTANT PROTEIN; NUCLEOTIDE; PHA 680626; PHENYLALANINE; POLO LIKE KINASE 1; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; SOLVENT; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CATALYSIS; CELL CYCLE PROGRESSION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG DESIGN; ENZYME ACTIVE SITE; ENZYME CONFORMATION; ENZYME KINETICS; ENZYME STRUCTURE; HUMAN; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FOLDING;

AMINO ACID SEQUENCE; BINDING SITES; CATALYTIC DOMAIN; CELL CYCLE PROTEINS; CRYSTALLOGRAPHY, X-RAY; ENZYME ACTIVATION; ENZYME STABILITY; HUMANS; KINETICS; MOLECULAR SEQUENCE DATA; PHOSPHORYLATION; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS;

EID: 34249076619     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi602474j     Document Type: Article

References (55)

1. Lowery, D. M., Lim, D., and Yaffe, M. B. (2005) Structure and function of Polo-like kinases, Oncogene 24, 248-259.
2. Barr, F. A., Sillje, H. H., and Nigg, E. A. (2004) Polo-like kinases and the orchestration of cell division, Nat. Rev. Mol. Cell Biol. 5, 429-440.
3. Strebhardt, K., and Ullrich, A. (2006) Targeting polo-like kinase 1 for cancer therapy, Nat. Rev. Cancer 6, 321-330.
4. Holtrich, U., Wolf, G., Brauninger, A., Karn, T., Bohme, B., Rubsamen-Waigmann, H., and Strebhardt, K. (1994) Induction and down-regulation of PLK, a human serine/threonine kinase expressed in proliferating cells and tumors. Proc. Natl. Acad. Sci. U.S.A. 91, 1736-1740.
5. Dietzmann, K., Kirches, E., von Bossanyi, P., Jachau, K., and Mawrin, C. (2001) Increased human polo-like kinase-1 expression in gliomas, J. Neurooncol. 53, 1-11.
6. Takai, N., Miyazaki, T., Fujisawa, K., Nasu, K., Hamanaka, R., and Miyakawa, I. (2001) Expression of polo-like kinase in ovarian cancer is associated with histological grade and clinical stage, Cancer Lett. 164, 41-49.
7. Takahashi, T., Sano, B., Nagata, T., Kato, H., Sugiyama, Y., Kunieda, K., Kimura, M., Okano, Y., and Saji, S. (2003) Polo-like kinase 1 (PLK1) is overexpressed in primary colorectal cancers. Cancer Sci. 94, 148-152.
8. Knecht, R., Elez, R., Oechler, M., Solbach, C., von Ilberg, C., and Strebhardt, K. (1999) Prognostic significance of polo-like kinase (PLK) expression in squamous cell carcinomas of the head and neck. Cancer Res. 59, 2794-2797.
9. Wolf, G., Elez, R., Doermer, A., Holtrich, U., Ackermann, H., Stutte, H. J., Altmannsberger, H. M., Rubsamen-Waigmann, H., and Strebhardt, K. (1997) Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer, Oncogene 14, 543-549.
10. Tokumitsu, Y., Mori, M., Tanaka, S., Akazawa, K., Nakano, S., and Niho, Y. (1999) Prognostic significance of polo-like kinase expression in esophageal carcinoma, Int. J. Oncol. 15, 687-692.
11. Kneisel, L., Strebhardt, K., Bernd, A., Wolter, M., Binder, A., and Kaufmann, R. (2002) Expression of polo-like kinase (PLK1) in thin melanomas: a novel marker of metastatic disease, J. Cutan. Pathol. 29, 354-358.
12. Lane, H. A., and Nigg, E. A. (1996) Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes, J. Cell Biol. 135, 1701-1713.
13. Spankuch-Schmitt, B., Wolf, G., Solbach, C., Loibl, S., Knecht, R., Stegmuller, M., von Minckwitz, G., Kaufmann, M., and Strebhardt, K. (2002) Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells, Oncogene 21, 3162-3171.
14. Liu, X., and Erikson, R. L. (2003) Polo-like kinase (Plk) 1 depletion induces apoptosis in cancer cells, Proc Natl. Acad. Sci. U.S.A. 100, 5789-5794.
15. Guan, R., Tapang, P., Leverson, J. D., Albert, D., Giranda, V. L., and Luo, Y. (2005) Small interfering RNA-mediated Polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals, Acta Crystallogr. D. Biol. Crystallogr. 65, 2698-2704.
16. Elez, R., Piiper, A., Kronenberger, B., Kock, M., Brendel, M., Hermann, E., Pliquett, U., Neumann, E., and Zeuzem, S. (2003) Tumor regression by combination antisense therapy against Plk1 and Bcl-2, Oncogene 22, 69-80.
17. Elia, A. E., Rellos, P., Haire, L. F., Chao, J. W., Ivins, F. J., Hoepker, K., Mohammad, D., Cantley, L. C., Smerdon, S. J., and Yaffe, M. B. (2003) The molecular basis for phosphodependent substrate targeting and regulation of Plks by the Polo-box domain, Cancer Sci. 115, 83-95.
18. Cheng, K. Y., Lowe, E. D., Sinclair, J., Nigg, E. A., and Johnson, L. N. (2003) The crystal structure of the human polo-like kinase-1 polo box domain and its phospho-peptide complex, EMBO J. 22, 5757-5768.
19. Lee, K. S., Grenfell, T. Z., Yarm, F. R., and Erikson, R. L. (1998) Mutation of the polo-box disrupts localization and mitotic functions of the mammalian polo kinase Plk, Proc Natl. Acad. Sci. U.S.A. 95, 9301-9306.
20. Elia, A. E., Cantley, L. C., and Yaffe, M. B. (2003) Proteomic screen finds pSer/pThr-binding domain localizing Plk1 to mitotic substrates, Science 299, 1228-1231.
21. Mundt, K. E., Golsteyn, R. M., Lane, H. A., and Nigg, E. A. (1997) On the regulation and function of human polo-like kinase 1 (PLK1): effects of overexpression on cell cycle progression, Biochem. Biophys. Res. Commun. 239, 377-385.
22. Jang, Y. J., Lin, C. Y., Ma, S., and Erikson, R. L. (2002) Functional studies on the role of the C-terminal domain of mammalian polo-like kinase, Proc Natl. Acad. Sci. U.S.A. 99, 1984-1989.
23. Golsteyn, R. M., Schultz, S. J., Bartek, J., Ziemiecki, A., Ried, T., and Nigg, E. A. (1994) Cell cycle analysis and chromosomal localization of human Plk1, a putative homologue of the mitotic kinases Drosophila polo and Saccharomyces cerevisiae Cdc5, J. Cell Sci. 107 (Pt 6), 1509-1517.
24. Cheng, L., Hunke, L., and Hardy, C. F. (1998) Cell cycle regulation of the Saccharomyces cerevisiae polo-like kinase cdc5p, Mol. Biol. Cell 18, 7360-7370.
25. Lindon, C., and Pines, J. (2004) Ordered proteolysis in anaphase inactivates Plk1 to contribute to proper mitotic exit in human cells, J. Cell Biol. 164, 233-241.
26. Lee, K. S., and Erikson, R. L. (1997) Plk is a functional homolog of Saccharomyces cerevisiae Cdc5, and elevated Plk activity induces multiple septation structures, Mol. Cell Biol. 17, 3408-3417.
27. Qian, Y. W., Erikson, E., and Maller, J. L. (1999) Mitotic effects of a constitutively active mutant of the Xenopus polo-like kinase Plx1, Mol. Cell Biol. 19, 8625-8632.
28. Jang, Y. J., Ma, S., Terada, Y., and Erikson, R. L. (2002) Phosphorylation of threonine 210 and the role of serine 137 in the regulation of mammalian polo-like kinase, J. Biol. Chem. 277, 44115-44120.
29. van de Weerdt, B. C., van Vugt, M. A., Lindon, C., Kauw, J. J., Rozendaal, M. J., Klompmaker, R., Wolthuis, R. M., and Medema, R. H. (2005) Uncoupling anaphase-promoting complex/cyclosome activity from spindle assembly checkpoint control by deregulating polo-like kinase 1, Mol. Cell. Biol. 25, 2031-2044.
30. Nolen, B., Taylor, S., and Ghosh, G. (2004) Regulation of protein kinases: Controlling activity through activation segment conformation, Mol. Cell 15, 661-675.
31. McInnes, C., Mezna, M., and Fischer, P. M. (2005) Progress in the discovery of polo-like kinase inhibitors, Curr. Top. Med. Chem. 5, 181-197.
32. Stevenson, C. S., Capper, E. A., Roshak, A. K., Marquez, B., Eichman, C., Jackson, J. R., Mattern, M., Gerwick, W. H., Jacobs, R. S., and Marshall, L. A. (2002) The identification and characterization of the marine natural product scytonemin as a novel antiproliferative pharmacophore, J. Pharmacol. Exp. Ther. 303, 858-866.
33. Liu, Y., Shreder, K. R., Gai, W., Corral, S., Ferris, D. K., and Rosenblum, J. S. (2005) Wortmannin, a widely used phosphoinositide 3-kinase inhibitor, also potently inhibits mammalian polo-like kinase, Chem. Biol. 12, 99-107.
34. Walker, E. H., Pacold, M. E., Perisic, O., Stephens, L., Hawkins, P. T., Wymann, M. P., and Williams, R. L. (2000) Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine, Mol. Cell 6, 909-919.
35. Steegmaier, M., Baum, A., Solca, F., Peters, J. M., Grauert, M., and Hoffmann, M. (2005) BI 2536, a potent and highly selective inhibitor of Polo-like kinase 1 (Plk1), induces mitotic arrest and apoptosis in a broad spectrum of tumor cell lines, Clin. Cancer Res. 11 (Suppl.), 9147.
36. Baum, A., Garin-Chesa, P., Quant, J., Colbatzky, F., Munzert, G., Grauert, M., Hoffmann, M., and Steegmaier, M. (2005) In vivo activity of BI 2536, a potent and selective inhibitor of the mitotic kinase Plk1, in a range of human cancer xenograft models, Clin. Cancer Res. 11 (Suppl.), 9146.
37. Mross, K., Steinbild, S., Frost, A., Hedborn, S., Rentschler, J., Kaiser, D., Trommeshauser, D., Stehle, G., and Munzetl, G. (2005) A Phase 1 single dose escalation study of the Polo-like kinase 1 inhibitor BI 2536 in patients with advanced solid tumors, Clin. Cancer Res. 11 (Suppl.), 9032.
38. McInnes, C., Meades, C., Mezna, M., and Fischer, P. (2004) PCT Int. Pat. Appl. Publ. WO 2004067000.
39. Umehara, H., Yamashita, Y., Tsujita, T., Arai, H., Hagihara, K., and Machii, D. (2004) PCT Int. Pat. Appl. Publ. WO 2004043936.
40. Davis-Ward, R., Mook, R. A. J., Neeb, M. J., and Salovich, J. M. (2004) PCT. Int. Pat. Appl. Publ. WO 2004074244.
41. Andrews, C. W., III, Cheung, M., Davis-Ward, R. G., Drewry, D. H., Emmitte, K. A., Hubbard, R. D., Kuntz, K. W., Linn, J. A., Mook, R. A., Smith, G. K., and Veal, J. M. (2004) PCT Int. Pat. Appl. Publ. WO 2004014899.
42. Fancelli, D., Berta, D., Bindi, S., Cameron, A., Cappella, P., Carpinelli, P., Catana, C., Forte, B., Giordano, P., Giorgini, M. L., Mantegani, S., Marsiglio, A., Meroni, M., Moll, J., Pittala, V., Roletto, F., Severino, D., Soncini, C., Storici, P., Tonani, R., Varasi, M., Vulpetti, A., and Vianello, P. (2005) Potent and selective Aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibition, J. Med. Chem. 48, 3080-3084.
43. Wasilko, D. J., and Lee, S. E. (2006) TIPS: Titerless infected-cells preservation and scale-up, BioProcess. J. 5, 29-32.
44. Segelke, B. (2005) Macromolecular crystallization with microfluidic free-interface diffusion, Expert Rev. Proteomics 2, 165-172.
45. Otinowski, Z., and Minor, W. (1997) Processing of X-ray diffraction data collected in oscillation mode, Methods Enzymol. 276, 307-326.
46. Collaborative Computational Project, Number 4. (1994) The CCP4 suite: programs for protein crystallography, Acta Crystallogr. D. Biol. Crystallogr. 50, 760-763.
47. Murshudov, G. N., Vagin, A. A., and Dodson, E. J. (1997) Refinement of macromolecular structures by the maximum-likelihood method, Acta Crystallogr. D. Biol. Crystallogr. 53, 240-255.
48. Oldfield, T. J., and Hubbard, R. H. (1994) Analysis of Cα geometry in protein structures, Protein: Struct.. Funct. Genet. 18, 324-337.
49. Pevarello, P., Brasca, M. G., Amici, R., Orsini, P., Traquandi, G., Corti, L., Piutti, C., Sansonna, P., Villa, M., Pierce, B. S., Pulici, M., Giordano, P., Martina, K., Fritzen, E. L., Nugent, R. A., Casale, E., Cameron, A., Ciomei, M., Roletto, F., Isacchi, A., Fogliatto, G., Pesenti, E., Pastori, W., Marsiglio, A., Leach, K. L., Clare, P. M., Fiorentini, F., Varasi, M., Vulpetti, A., and Warpehoski, M. A. (2004) 3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 1. Lead finding, J. Med. Chem. 47, 3367-3380.
50. Hanks, S., and Hunter, T. (1995) Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification, FASEB J. 9, 576-596.
51. Zheng, J., Knighton, D. R., ten Eyck, L. F., Karlsson, R., Xuong, N., Taylor, S. S., and Sowadski, J. M. (1993) Crystal structure of the catalytic subunit of cAMP-dependent protein kinase complexed with MgATP and peptide inhibitor, Biochemistry 32, 2154-2161.
52. Yang, J., Cron, P., Good, V. M., Thompson, V., Hemmings, B. A., and Barford, D. (2002) Crystal structure of an activated Akt/Protein Kinase B ternary complex with GSK3-peptide and AMP-PNP, Nat. Struct. Biol. 9, 940-944.
53. Biondi, R. M., Komander, D., Thomas, C. C., Lizcano, J. M., Deak, M., Alessi, D. R., and van Aalten, D. M. F. (2002) High resolution crystal structure of the human PDK1 catalytic domain defines the regulatory phosphopeptide docking site, EMBO J. 21, 4219-4228.
54. Krupa, A., Preethi, G., and Srinivasan, N. (2004) Structural modes of stabilization of permissive phosphorylation sites in protein kinases: Distinct strategies in Ser/Thr and Tyr kinases, J. Mol. Biol. 339, 1025-1039.
55. Cohen, M. S., Zhang, C., Shokat, K. M., and Taunton, J. (2005) Structural bioinformatics-based design of selective, irreversible kinase inhibitors, Science 308, 1318-1321.